SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Josephine Baker Synthetic CCD

PatientJosephine Baker
Date of birth1963-06-03
IdentifiersMRN HR-ML049-SYN; SSN (made up) 000-49-3172
Document date2026-11-01
AuthorColette Ashby-Nwosu, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Establishing care three weeks after a heart attack and stent, with breathlessness on exertion and tiredness: examination, ECG, laboratory tests, medicines, mood screening, cardiac rehabilitation and the chest-pain action plan. Concerns: She wants to return to the stage and to have the strength to care for her children; She is afraid of another heart attack and of what would happen to her family; Debts and lost income make every cost a worry. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Aspirin 81 mg delayed-release oral tablet, one tablet dailyOne tablet dailyOral route2026-03-24activeS
Ticagrelor 90 mg oral tablet, one tablet twice dailyOne tablet twice dailyOral route2026-03-24 to 2026-04-28completedS
Clopidogrel 75 mg oral tablet: a 600 mg loading dose (eight tablets) 24 hours after the last ticagrelor, then one tablet dailyOne tablet daily after a 600 mg loading doseOral route2026-04-28activeS
Atorvastatin 80 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-24activeS
Metoprolol succinate 25 mg extended-release oral tablet, one tablet dailyOne tablet dailyOral route2026-03-24activeS
Lisinopril 5 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-24 to 2026-04-28completedS
Lisinopril 10 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-04-28activeS
Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if the pain is not better 5 minutes after the first tabletOne tablet under the tongue every 5 minutes as needed for chest pain, up to 3 dosesSublingual route2026-03-24activeS

Procedures

ProcedureDatesStatusEvidence
Coronary angiography and percutaneous coronary intervention in the hospital for a non-ST-elevation myocardial infarction: 90% stenosis of the mid right coronary artery treated with one drug-eluting stent; mild disease elsewhere. Performed at a regional hospital before she established care2026-03-24 to 2026-03-24completedS
Twelve-lead electrocardiogram: sinus rhythm at 64 per minute, small Q waves in II, III and aVF from the recent inferior infarction, no acute ST change, normal QT2026-04-14 to 2026-04-14completedS
Outpatient cardiac rehabilitation, phase 2: 36 sessions over twelve weeks with exercise training, nutrition, stress management and psychological support; all sessions completed2026-04-21 to 2026-07-17completedS
Transthoracic echocardiography: ejection fraction 52%, hypokinesis of the basal and mid inferior wall, normal right ventricle, no thrombus, normal valves, normal estimated filling pressures, no pericardial effusion2026-04-28 to 2026-04-28completedS
Symptom-limited exercise treadmill test on her usual medicines (Bruce protocol): 9 minutes, about 10 METs, peak heart rate 132 per minute on metoprolol, normal blood pressure response (124/76 to 172/80), no angina, no ischemic ST change, no arrhythmia2026-07-21 to 2026-07-21completedS
Advance care planning conversation, about 20 minutes, with her consent2026-09-15 to 2026-09-15completedS

Immunizations

DateVaccineStatusEvidence
2026-09-15Influenza vaccine, this seasoncompletedS
2026-09-15COVID-19 vaccine, mRNA, this seasoncompletedS
2026-09-15Pneumococcal conjugate vaccine PCV20, single dosecompletedS
2026-10-20Respiratory syncytial virus vaccine, single dosecompletedS
2026-10-20Recombinant zoster vaccine, dose 1 of 2completedS
2026-10-20Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
June 1941 to December 1942Long, grave illness in Casablanca after the loss of a pregnancy: in bed in hospital from June 1941 to December 1942, with five operations, reportedly including an emergency hysterectomy, and peritonitis and septicemia (details from one secondary source; stillbirth or miscarriage disputed)R (CLM-0007, CLM-0008)
March 1969Heart attack in March 1969, on the day of her eviction from Les Milandes, with admission to hospital in Périgueux; described as a new heart attack, with any earlier one undated in the sources readD (CLM-0011)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
She wants to return to the stage and to have the strength to care for her childrenactiveS
She is afraid of another heart attack and of what would happen to her familyactiveS
Debts and lost income make every cost a worryactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 12.4 on 2026-10-20; Platelets [#/volume] in Blood by Automated count 258 on 2026-06-16; Sodium [Moles/volume] in Serum or Plasma 139 on 2026-10-20; Potassium [Moles/volume] in Serum or Plasma 4.5 on 2026-10-20; Creatinine [Mass/volume] in Serum or Plasma 0.84 on 2026-10-20; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 78 on 2026-10-20; Glucose [Mass/volume] in Serum or Plasma 93 on 2026-10-20; Cholesterol [Mass/volume] in Serum or Plasma 128 on 2026-07-21; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 62 on 2026-07-21; Cholesterol in HDL [Mass/volume] in Serum or Plasma 54 on 2026-07-21; Triglyceride [Mass/volume] in Serum or Plasma 72 on 2026-07-21; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 on 2026-07-21; Hemoglobin A1c/Hemoglobin.total in Blood 5.6 on 2026-04-14; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-09-15; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-07-21; Overall summary score [SAQ] 96 on 2026-10-20; Lipoprotein a [Moles/volume] in Serum or Plasma 172 on 2026-04-28; Left ventricular Ejection fraction 52 on 2026-04-28; Total score [AUDIT-C] 1 on 2026-09-15 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Breathlessness on exertion and tiredness since discharge three weeks after the heart attack, without chest pain at rest; cause to be determined (heart function, ischemia, anemia, medicine effect or deconditioning)resolvedconfirmed R06.09S — Synthetic presenting problem, resolved at the second visit when the echocardiogram and cardiology attributed it to ticagrelor.
Coronary artery disease after a non-ST-elevation myocardial infarction three weeks before intake, treated with one drug-eluting stent to the right coronary artery; synthetic modern episode linked to the documented heart attack of March 1969activeconfirmed I25.10S — Synthetic modern diagnosis; the 1969 heart attack remains D in the history.
High blood pressure, found during the hospital stay for the heart attackactiveconfirmed I10S — Synthetic modern diagnosis; no claim about her real blood pressure.
Absence of the uterus after an emergency hysterectomy at about 35, during a long, grave illness after the loss of a pregnancy; whether the ovaries were removed is not known; counted as a possible early menopause when weighing her cardiovascular riskactiveprovisional Z90.710S — Synthetic modern status linked to the retrospective account of a hysterectomy in 1941 or 1942; the operation itself rests on one secondary source.
Breathlessness from ticagrelor: a common, harmless side effect, resolved after the change to clopidogrelresolvedconfirmed T45.525AS — Synthetic diagnosis at the second visit; resolved at the third visit after the switch.
Raised lipoprotein(a), 172 nmol/L, an inherited risk-enhancing factoractiveconfirmed E78.41S — Synthetic result measured once at the second visit.
Financial strain: heavy debts after the loss of her home and estate, with income only from performing, which she has stopped while she recoversactiveconfirmed Z59.86S — Synthetic social need anchored to her documented debts and the loss of Les Milandes.
Anterior nosebleed from the left side of the nose, lasting about 25 minutes, in dry weather on aspirin and clopidogrel; stopped with pressure; no further bleedingresolvedconfirmed R04.0S — Synthetic intercurrent problem at an unscheduled visit; it follows from dual antiplatelet therapy and does not echo a documented illness.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-14Hemoglobin [Mass/volume] in Blood12.2g/dL11.6-15 g/dLNormalS
2026-04-14Platelets [#/volume] in Blood by Automated count26410*3/uL150-400 10*3/uLNormalS
2026-04-14Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-04-14Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
2026-04-14Creatinine [Mass/volume] in Serum or Plasma0.82mg/dL0.59-1.04 mg/dLNormalS
2026-04-14Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M81mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-04-14Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS
2026-04-14Cholesterol [Mass/volume] in Serum or Plasma152mg/dL<=199 mg/dLNormalS
2026-04-14Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation84mg/dLSecondary-prevention goal below 70 mg/dLHighS
2026-04-14Cholesterol in HDL [Mass/volume] in Serum or Plasma52mg/dL>=50 mg/dLNormalS
2026-04-14Triglyceride [Mass/volume] in Serum or Plasma80mg/dL<=149 mg/dLNormalS
2026-04-14Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L7-35 U/LNormalS
2026-04-14Hemoglobin A1c/Hemoglobin.total in Blood5.6%<=5.6%NormalS
2026-04-14Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]2{score}S
2026-04-14Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S
2026-04-14Overall summary score [SAQ]70{score}S
2026-04-28Lipoprotein a [Moles/volume] in Serum or Plasma172nmol/L125 nmol/L or higher is a risk-enhancing levelHighS
2026-04-28Left ventricular Ejection fraction52%50-70%NormalS
2026-05-26Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-05-26Potassium [Moles/volume] in Serum or Plasma4.7mmol/L3.5-5.1 mmol/LNormalS
2026-05-26Creatinine [Mass/volume] in Serum or Plasma0.88mg/dL0.59-1.04 mg/dLNormalS
2026-05-26Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M74mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-05-26Glucose [Mass/volume] in Serum or Plasma92mg/dL70-99 mg/dLNormalS
2026-05-26Overall summary score [SAQ]84{score}S
2026-06-16Hemoglobin [Mass/volume] in Blood11.9g/dL11.6-15 g/dLNormalS
2026-06-16Platelets [#/volume] in Blood by Automated count25810*3/uL150-400 10*3/uLNormalS
2026-07-21Cholesterol [Mass/volume] in Serum or Plasma128mg/dL<=199 mg/dLNormalS
2026-07-21Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation62mg/dLSecondary-prevention goal below 70 mg/dLNormalS
2026-07-21Cholesterol in HDL [Mass/volume] in Serum or Plasma54mg/dL>=50 mg/dLNormalS
2026-07-21Triglyceride [Mass/volume] in Serum or Plasma72mg/dL<=149 mg/dLNormalS
2026-07-21Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-35 U/LNormalS
2026-07-21Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
2026-07-21Overall summary score [SAQ]94{score}S
2026-09-15Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2026-10-20Hemoglobin [Mass/volume] in Blood12.4g/dL11.6-15 g/dLNormalS
2026-10-20Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-10-20Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
2026-10-20Creatinine [Mass/volume] in Serum or Plasma0.84mg/dL0.59-1.04 mg/dLNormalS
2026-10-20Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M78mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-20Glucose [Mass/volume] in Serum or Plasma93mg/dL70-99 mg/dLNormalS
2026-10-20Overall summary score [SAQ]96{score}S
2026-09-15Total score [AUDIT-C]1{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-04-14Body height168cmS
2026-04-14Body weight59.8kgS
2026-04-14Body mass index (BMI) [Ratio]21.2kg/m2S
2026-04-14Systolic blood pressure138mm[Hg]S
2026-04-14Diastolic blood pressure84mm[Hg]S
2026-04-14Heart rate64/minS
2026-04-14Respiratory rate16/minS
2026-04-14Body temperature36.6CelS
2026-04-14Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-04-28Body height168cmS
2026-04-28Body weight59.6kgS
2026-04-28Body mass index (BMI) [Ratio]21.1kg/m2S
2026-04-28Systolic blood pressure136mm[Hg]S
2026-04-28Diastolic blood pressure82mm[Hg]S
2026-04-28Heart rate62/minS
2026-04-28Respiratory rate16/minS
2026-04-28Body temperature36.7CelS
2026-04-28Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-05-26Body height168cmS
2026-05-26Body weight59.9kgS
2026-05-26Body mass index (BMI) [Ratio]21.2kg/m2S
2026-05-26Systolic blood pressure126mm[Hg]S
2026-05-26Diastolic blood pressure78mm[Hg]S
2026-05-26Heart rate60/minS
2026-05-26Respiratory rate14/minS
2026-05-26Body temperature36.6CelS
2026-05-26Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-07-21Body height168cmS
2026-07-21Body weight60.4kgS
2026-07-21Body mass index (BMI) [Ratio]21.4kg/m2S
2026-07-21Systolic blood pressure122mm[Hg]S
2026-07-21Diastolic blood pressure76mm[Hg]S
2026-07-21Heart rate58/minS
2026-07-21Respiratory rate14/minS
2026-07-21Body temperature36.5CelS
2026-07-21Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-10-20Body height168cmS
2026-10-20Body weight60.6kgS
2026-10-20Body mass index (BMI) [Ratio]21.5kg/m2S
2026-10-20Systolic blood pressure122mm[Hg]S
2026-10-20Diastolic blood pressure74mm[Hg]S
2026-10-20Heart rate58/minS
2026-10-20Respiratory rate14/minS
2026-10-20Body temperature36.6CelS
2026-10-20Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-06-16Body height168cmS
2026-06-16Body weight60.2kgS
2026-06-16Body mass index (BMI) [Ratio]21.3kg/m2S
2026-06-16Systolic blood pressure132mm[Hg]S
2026-06-16Diastolic blood pressure80mm[Hg]S
2026-06-16Heart rate70/minS
2026-06-16Respiratory rate16/minS
2026-06-16Body temperature36.6CelS
2026-06-16Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-09-15Body height168cmS
2026-09-15Body weight60.6kgS
2026-09-15Body mass index (BMI) [Ratio]21.5kg/m2S
2026-09-15Systolic blood pressure124mm[Hg]S
2026-09-15Diastolic blood pressure76mm[Hg]S
2026-09-15Heart rate58/minS
2026-09-15Respiratory rate14/minS
2026-09-15Body temperature36.6CelS
2026-09-15Oxygen saturation in Arterial blood by Pulse oximetry99%S

Encounters

DatePurposeStatusProvenance
2026-04-14Establishing care three weeks after a heart attack and stent, with breathlessness on exertion and tiredness: examination, ECG, laboratory tests, medicines, mood screening, cardiac rehabilitation and the chest-pain action planfinishedS
2026-04-28Two-week review: echocardiogram, cardiology consultation the same day, the cause of the breathlessness and the antiplatelet planfinishedS
2026-05-26Four-week review after the change to clopidogrel: breathlessness, blood pressure, potassium and kidney function, and cardiac rehabilitationfinishedS
2026-07-21Twelve-week review: exercise test, lipids, mood, and the return to performingfinishedS
2026-10-20Seven-month review: antiplatelet plan to twelve months, blood pressure, kidney function, angina status and plans for the yearfinishedS
2026-06-16Same-day sick visit for a nosebleed on dual antiplatelet therapyfinishedS
2026-09-15Periodic adult preventive visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Respectful, trauma-informed shared decisions: take her account of her symptoms seriously, explain each medicine and its reason plainly, write the plan down, and check costs with her before prescribingcompletedGL-AHA-WOMEN-MI-2016, GL-GWTG-DISPARITY-2016, GL-CCD-2023S
Cardiology consultation on the day of the two-week visit, with an echocardiogram, to find the cause of the breathlessness, review the antiplatelet choice and the other medicines, and advise on rehabilitation and a return to the stagecompletedGL-CCD-2023, GL-ACS-2025, GL-CMID-2026S
Dual antiplatelet therapy, aspirin 81 mg with a P2Y12 inhibitor, for twelve months from the heart attack, never stopped without speaking to cardiology; then aspirin alonecompletedGL-ACS-2025, GL-CCD-2023, GL-CMID-2026S
Atorvastatin 80 mg daily; lipid panel four to eight weeks after the start; goal LDL below 70 mg/dL with at least a 50% fall; lipoprotein(a) measured oncecompletedGL-CCD-2023, GL-CMID-2026S
Metoprolol succinate for at least the first year after the heart attack; lisinopril for high blood pressure, with home readings and a target below 130/80 mmHg; potassium and creatinine one to two weeks after any dose changecompletedGL-CCD-2023, GL-CMID-2026S
Enroll in a 36-session outpatient cardiac rehabilitation program, starting within two weeks, with exercise training, nutrition, stress management and psychological support; the clinic will call her if she misses sessionscompletedGL-CCD-2023, GL-AHA-WOMEN-MI-2016, GL-CMID-2026S
Depression after a heart attack: PHQ-2 and PHQ-9 today, repeat PHQ-9 at about twelve weeks, the rehabilitation program's psychologist, and a lower threshold for treatment if symptoms risecompletedGL-AHA-DEP-2008, GL-AHA-DEP-ACS-2014, GL-CCD-2023S
Chest-pain action plan: nitroglycerin under the tongue, and 911 if pain is not better five minutes after the first tablet; warning symptoms in women, such as breathlessness, unusual tiredness, nausea or jaw, back or arm discomfort, explainedcompletedGL-AHA-WOMEN-MI-2016, GL-CCD-2023S
Costs: generic medicines in 90-day fills, the clinic social worker for debt advice and help with medicine costs, and rehabilitation sessions at times that fit her familycompletedGL-CCD-2023S
Women's cardiovascular risk: record the hysterectomy of her thirties and a possible early menopause as a risk-enhancing factor; hormone therapy is not used to prevent heart diseasecompletedGL-AHA-MENO-2020, GL-AHA-WOMEN-MI-2016S
Change ticagrelor to clopidogrel for ticagrelor-related breathlessness: 600 mg loading dose 24 hours after the last ticagrelor, then 75 mg daily, without a gap in antiplatelet covercompletedGL-ACS-2025, GL-CCD-2023S
Raise lisinopril to 10 mg daily for blood pressure above target, with potassium and creatinine one to two weeks latercompletedGL-CCD-2023, GL-CMID-2026S
Laboratory tests drawn at the rehabilitation center on session days, so that no check needs a separate tripcompletedGL-CMID-2026S
Nosebleed plan on dual antiplatelet therapy: firm pressure on the soft part of the nose for 15 minutes, saline spray and a humidifier; do not stop aspirin or clopidogrel; come in if bleeding lasts more than 30 minutescompletedGL-AAO-EPISTAXIS-2020, GL-ACS-2025S
Graded return to the stage: rehearsals at the effort reached in rehabilitation, then full performances, with rest between shows, water, and nitroglycerin in the dressing roomcompletedGL-CCD-2023S

Goals

GoalTargetStatusOutcomeProvenance
Twelve months of dual antiplatelet therapy from the heart attack without interruption2027-03-24activeSeven months completed without a missed dose; changed from ticagrelor to clopidogrel without a gapS
LDL cholesterol below 70 mg/dL with at least a 50% fall2026-07-21completedLDL 62 mg/dL, a 58% fall from 146S
Blood pressure below 130/80 mmHg2026-05-26completed126/78 in the clinic; home average 124/76S
Complete cardiac rehabilitation and return to performing2026-07-21completedExercise test to about 10 METs without ischemia; graded return to rehearsals agreedS
Mood: PHQ-9 below 5 by twelve weeks2026-07-21completedPHQ-9 7 to 3S

Functional Status

Mental Status